JIR
JAZZ icon

James Investment Research’s Jazz Pharmaceuticals JAZZ Stock Holding History

James Investment Research’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,620
Closed -$231K – 605
2019
Q2 		$231K Sell
1,620
-3,395
-68% -$456K 0.02% 328
2019
Q1 		$717K Buy
+5,015
New +$654K 0.05% 290
2018
Q4 		– Sell
-12,820
Closed -$2.15M – 849
2018
Q3 		$2.15M Buy
+12,820
New +$2.2M 0.09% 297

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

James Investment Research's JAZZ Position: Q3 2019 in Review

James Investment Research sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 1,620 shares — an estimated $231K sold.

James Investment Research first reported a position in JAZZ in Q3 2018 and held it in 3 quarters. The position peaked at $2.15M in Q3 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • James Investment Research reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • James Investment Research sold 1,620 Jazz Pharmaceuticals shares in Q3 2019, an estimated $231K.
  • James Investment Research first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • James Investment Research's Jazz Pharmaceuticals position peaked at $2.15M in Q3 2018.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on James Investment Research's 13F filing for Q3 2019, filed 30 Oct 2019.